Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 2/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | MMP3 | P08254 | 1/20 | 0.30 |
| ▸ | CHKA | P35790 | 1/20 | 0.30 |
| ▸ | MMP1 | P03956 | 1/20 | 0.30 |
| ▸ | MMP2 | P08253 | 1/20 | 0.30 |
| ▸ | MMP8 | P22894 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16524150 | 1.00 | HPGD (0.34) | HPGDCHRM5CHRM3CA2CA12 | |
| SCHEMBL9103905 | 0.83 | CYP3A4 (0.42) | — | |
| SCHEMBL5007792 | 0.75 | CHRM5 (0.37) | CHRM5CHRM3 | |
| SCHEMBL1622973 | 0.71 | MMP1 (0.40) | HPGDCHRM5CHRM3CA2CA12 | |
| SCHEMBL1622976 | 0.71 | MMP1 (0.40) | HPGDCHRM5CHRM3CA2CA12 | |
| Oxalic Acid SCHEMBL1623880 | 0.70 | MMP1 (0.37) | HPGDCHRM5CHRM3CA2CA12 | |
| Oxalic Acid SCHEMBL1623877 | 0.70 | MMP1 (0.37) | HPGDCHRM5CHRM3CA2CA12 | |
| SCHEMBL2499332 | 0.69 | RNPEP (0.31) | MMP1MMP2MMP8 | |
| SCHEMBL6087664 | 0.69 | DPP4 (0.44) | CHRM5CHRM3CA2CA12CA1 | |
| SCHEMBL6087667 | 0.69 | DPP4 (0.44) | CHRM5CHRM3CA2CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160024093-A1 | IMIDAZO[1,2-b]PYRIDAZINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS INC (US) | 2016-01-28 | — | — | US | disclosed |
| US-8969565-B2 | Imidazo[1,2-b]pyridazine-based compounds, compositions comprising them, and methods of their use | LEXICON PHARMACEUTICALS, INC. (US) | 2015-03-03 | — | — | US | disclosed |
| US-20080318945-A1 | Novel Compounds | CASILLAS LINDA N | 2008-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318945-A1 | Novel Compounds | TRPV4, TRPV1, TRPV3 | HPGD 1915/4885CHRM5 313/4885CHRM3 209/4885 |
| US-20160024093-A1 | IMIDAZO[1,2-b]PYRIDAZINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE | IRAK2, IRAK1, GRB2 | HPGD 4028/4885CHRM5 3962/4885CHRM3 2934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.